Coronary atherosclerosis (GLAGOV study)
header logo

Terms of Use

The information contained on this site is for healthcare professionals only.

I am a healthcare professional from
Choose a Country ▼

REPATHA®
DELIVERS
CONSISTENT,
INTENSIVE LDL-C
LOWERING1

Repatha® and coronary atherosclerosis burden

  • Repatha® reduced percent atheroma volume (PAV)* by 0.95% and normalised total atheroma volume by 5.8 mm3 (both p<0.001 vs placebo)2
  • 64.3% of Repatha® patients showed regression in PAV vs 47.3% of placebo patients (p<0.001)2

Change from baseline in PAV at Week 782

GLAGOV was a 78-week, double-blind, randomised, placebo-controlled study in 968 patients with coronary artery disease receiving stable, optimised statin therapy.2
The study assessed the effects of Repatha® on atherosclerotic disease burden, as measured by intravascular ultrasound (IVUS).2

*The primary endpoint was change in PAV from baseline to Week 78. PAV regression was defined as any reduction in PAV from baseline to Week 78. Secondary efficacy measures were nominal change in normalised total atheroma volume (TAV) and percentage of patients demonstrating plaque regression. Safety and tolerability were also evaluated.
In the study, 2690 recent MI patients received Repatha®, 2254 of whom achieved LDL-C levels <55 mg/dl.
25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; CV = Cardiovascular; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; EVOPACS = EVOlocumab for Early Reduction of
LDL-cholesterol Levels in Patients With Acute Coronary Syndromes; GLAGOV = GLobal Assessment of Plaque ReGression With a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound; IVUS = Intravascular ultrasound; LDL-C = Low-density lipoprotein cholesterol; MI = Myocardial infarction; NS = Non-significant; PAV = Percent atheroma volume; PCSK9 = Protein convertase subtilisin/kexin type 9; RRR = Relative risk reduction.
  1. Repatha® (evolocumab) Summary of Product Characteristics. Last revised: April 2020.
  2. Nicholls SJ, et al. JAMA. 2016;316:2373-84.
  3. Gencer B, et al. JAMA Cardiol. 2020; Online first. doi:10.1001/jamacardio.2020.0882.

By clicking the 'DOWNLOAD' button below you will immediately begin downloading the Reporting Systems Appendix
Return to previous page DOWNLOAD